Related Experiment Video
Updated: Dec 6, 2025
04:21
Lumican Extraction from Amniotic Membrane and Determination of its Storage Temperature
Published on: October 14, 2022
1.7K
Self-retained cryopreserved amniotic membrane for treating severe corneal ulcers: a comparative, retrospective
Han Y Yin1,2, Anny M S Cheng3,4, Sean Tighe3,5,6
1Department of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Suit L 550 Harrison St, Syracuse, NY, 13202, USA. hhyin003@gmail.com.
Scientific Reports
|October 13, 2020
Summary
Cryopreserved amniotic membrane (AM) significantly speeds healing and improves vision in patients with infectious corneal ulcers. This adjuvant therapy promotes faster epithelialization and better visual acuity recovery compared to standard treatment.
Area of Science:
- Ophthalmology
- Regenerative Medicine
- Corneal Disease Research
Background:
- Infectious corneal ulcers can lead to significant vision loss.
- Standard treatments may not always restore visual acuity effectively.
- Amniotic membrane (AM) has regenerative properties beneficial for ocular surface healing.
Purpose of the Study:
- To evaluate the efficacy of cryopreserved amniotic membrane (AM) as an adjuvant therapy for infectious corneal ulcers.
- To compare epithelialization rates and visual acuity outcomes between patients receiving AM and those not receiving AM.
Main Methods:
- Retrospective case-control study involving 24 patients with infectious corneal ulcers.
- 11 patients received additional self-retained cryopreserved AM.
- Comparison of epithelialization time, complete epithelialization rates, and best-corrected visual acuity (BCSVA).
Main Results:
- Patients receiving cryopreserved AM showed significantly faster epithelialization (3.56 weeks vs. 5.87 weeks).
- Higher rates of complete epithelialization were observed in the AM group (72.7% vs. 23.1%).
- The AM group achieved better visual acuity outcomes, including clinically significant BCSVA improvement (81.8% vs. 38.4%).
Conclusions:
- Sutureless, in-office cryopreserved AM is an effective adjuvant therapy for sight-threatening infectious corneal ulcers.
- AM promotes accelerated corneal epithelialization and enhances overall visual recovery.
- This approach offers a promising strategy for managing severe corneal infections.
